Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Apogee Therapeutics Inc APGE

Healthcare Biotechnology
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:APGE)

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

GlobeNewswire 5 hours ago

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

GlobeNewswire 6 days ago

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire November 4, 2024

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire October 24, 2024

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

GlobeNewswire October 16, 2024

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

GlobeNewswire September 12, 2024

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

GlobeNewswire September 9, 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

GlobeNewswire August 19, 2024

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

GlobeNewswire August 12, 2024
View More News ››

Opinion & Analysis (NDAQ:APGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:APGE)

Be the first to post on this bullboard.

NurExone Biologic Inc.

NurExone Biologic Inc.

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ...
View More »